Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
Category: #health  By Mateen Dalal  Date: 2019-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
  • Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB.
  • In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethasone and melflfufen in RRMM patients suffering from EMD.

Oncopeptides AB, a pharmaceutical company established in 2000 aimed at developing drugs to treat cancer, reportedly announced interim safety and efficacy data update from the ongoing Phase 2 HORIZON trial during 17th International Myeloma Workshop (IMW) being conducted at Boston, Massachusetts, USA.  

The outcomes presented during IMW 2019 by Prof. Paul G Richardson during the plenary session “Late Breaking Abstracts” with title name: Activity of Melflufen in RRMM Patients with EMD(Extramedullary Disease) in Phase 2 Study (OP-106 HORIZON) – promising outcomes in a high-risk population, are further based on a data cur from the company’s HORIZON trial conducted in July of 2019 when 136 participants were treated in comparison to earlier reported data which included 121 patients.

HORIZON represents the biggest clinical cohort based on literature till date of patients having myeloma that are diagnosed with extra medullary disease (EMD).

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) is a population that is highly difficult to treat. In very recent single-agent trial (without or with steroids) comprising RRMM patients having EMD have demonstrated overall response rates (ORR) falling between 0 – 17%.

Only daratumumab has been able to show any relavant clinical activity having an overall response rate of 17% in patients with daratumumab naïve myeloma with EMD.

In the HORIZON trial, an ORR (overall response rate) of 23% was achieved when treated with dexamethasone and melflfufen in RRMM patients suffering from EMD. Mainly, penta refractory patients were found under this category (who have undergone five prior treatments at least and were resistant to a minimum of one proteasome inhibitor, one anti-CD38 and IMiD treatment).

Source credit: https://www.oncopeptides.se/en/new-interim-data-in-rrmm-patients-with-extramedullary-disease-from-the-pivotal-phase-2-horizon-study-presented-at-international-myeloma-workshop/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...